JUBLPHARMABSEJubilant Pharmova LtdHighNegative
Announced Fri, 22 May · 14:40 IST

Change in CFO

Cfo ResignedKmp ResignedManagement Changes View source PDF

JUBLPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-1.1%1-day move
₹1011.00
prior close
₹1013.70
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.8-0.6-0.6-0.6-1.1-2.1-2.1-1.8-3.4-3.2-2.0-5.5-2.1
Up moveDown movePending
AI summary

Jubilant Pharmova has announced a CFO change effective May 22-23, 2026. Mr. Arun Kumar Sharma stepped down as CFO and will now serve as Advisor to the Chairmen. The Board has appointed Mr. Ashish Mukkirwar as the new CFO and Key Managerial Personnel starting May 23, 2026. Ashish Mukkirwar joins from Glenmark Pharmaceuticals where he served as Group Vice President & CFO - Global Formulations Business, bringing over two decades of experience in corporate finance, M&A, and investor relations from firms including Moelis & Company and UBS Investment Banking. The Board expressed appreciation for Arun Kumar Sharma's contributions during his tenure.

Likely market impact

This is a routine executive transition as the outgoing CFO moves to an advisory role internally. The appointment of an experienced external candidate with pharmaceutical industry experience and investment banking background may be viewed positively by investors. No immediate impact on operations expected.